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Abstract
Potassium ion channels are transmembrane proteins that se-
lectively facilitate ion flow down an electrochemical gradient 
between intracellular and extracellular environments. There is 
accumulating evidence which suggest that potassium channel 
protein activity is important in the pathophysiology of cancer, 
and associations of the two-pore domain family of potassium 
channels and breast cancer are currently emerging. The aim of 
this review is to summarize data on mechanisms of action relat-
ed to oncogenic properties and examine the role of the two-pore 
domain family in breast cancer.
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Abbreviations
CpG :  Cytosine-Guanine
ER/PR :  Estrogen/Progesterone Receptor
HER2 :  Human Epidermal Growth Factor Receptor-2
K+ :  Potassium
Kv :  Voltage-Gated K+ Channels
KCa : Calcium-Activated K+ Channels
Kir :  Inward-Rectifier K+ Channels
K2p :  2-Pore Domain K+ Channels
LOM :  Loss of Methylation
nH :  non-Hispanic 
TN :  Triple-Negative
Potassium Ion Channel Proteins and 
Mechanisms of Action in Cancer
There is accumulating evidence which supports the role of sev-
eral types of ion channels in the pathophysiology of cancer [1,2]. 
Potassium (K+) channels are transmembrane proteins that se-
lectively facilitate the flow of K+ ions down an electrochemical 
gradient between intracellular and extracellular environments 
[3,4]. K+ channels are the most diverse and ubiquitous class of 
ion channels and control membrane potential, are involved in 
several physiological functions, and contribute to nerve and car-
diac action potentials and neurotransmitter release [1].
K+ channels can be classified according to a combination of 
stimulus, conductance properties and structural criteria which 
produces 4 classes: (1) voltage-gated (Kv); (2) calcium-acti-
vated (KCa); (3) inward-rectifier (Kir); and (4) 2-pore-domain 
(K2p) [3,4]. K+ channels typically have a basic conserved sub-
unit structure that consists of 2 transmembrane domains and 
a hairpin structure, known as the pore-forming loop (P-loop); 
these subunits associate to form channels and are encoded by 
79 genes [5]. Among ion transporters, K+ channels show the 
highest variability and the most frequently altered expression in 
many tumor types [4].
K+ channels have essential roles in cell behaviors linked to can-
cer, and highly proliferating cells display a more positive cell 
membrane potential (an activity driven by K+ channels) than 
quiescent cells [6]. Importantly, cell cycle and proliferation, cell 
migration, invasion and apoptosis are all processes that can be 
modified by K+ channel expression and potentially offer the op-
portunity for novel therapeutic manipulation [3,4]. With respect 
to control of K+ channel gene expression in tumors, changes in 
the expression levels in tumors can occur at the genomic, tran-
scriptional, post-translational or epigenetic levels, and in some 
cases a quantitative increase in activity can be explained by up-
stream changes. In most tumors, the abnormally expressed chan-
nel is wild type [3,4]. However, a small clinical study genotyped 
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22 patients with Aldosterone-Producing Adrenal Adenomas 
(APAs) and found associated mutations in the pore-forming loop 
of the inward-rectifier Kir3.4 which is encoded by KCNJ5 [7].
Altered K+ channel expression and/or function occurs in a range 
of cancer types including breast cancer, and ion channels from 
each of the four main K+ channel families have been implicated.
This evidence is summarized below except for K2p genes which 
is addressed separately in a following section.Recent publica-
tions by Pardo and Stuhmer and Comes et al., provide a more 
in-depth review of the potential roles of K+ channels in cancer 
[1,2].
Enhancement of tumor cell migration
Kv10.1 (a.k.a. Human ether à-gogo, HERG1) has been found 
to regulate MDA-MB-231 breast cancer cell migration in a lab-
oratory study on cell lines [8]. Additional cell line studies sug-
gest that Kv11.1 is also implicated in the migration of leukemia, 
melanoma and thyroid cancer cells [9-12]. Malignant neural cell 
studies have also shown that KCa1.1 and KCa3.1 appear to be 
important for the migration of glioma cells [13-17]. Further-
more, a small conductance subfamily member KCa2.3 (or SK3) 
appears to mediate migration and metastasis of malignant colon, 
breast cancer and melanoma cells [18-21].
Involvement of tumor proliferation and apoptosis
Kv10.1 overexpression has been implicated in malignant trans-
formation and proliferation in several tumor cell lines including 
neuroblastoma [22]. Another laboratory study suggested that 
Kv10.1 also plays a role in controlling the proliferation and/or 
cell cycle of MCF-7 breast cancer cells [23]. The initiation of 
apoptosis appears to be associated with cell volume change and 
a decrease in intracellular K+[24]. In medulloblastoma cell line 
studies, forced expression of Kv10.2 in heterologous systems 
(HEK-293 cells) led to reduced cell volume and increased ap-
optosis [25]. In glioblastoma cells, KCa3.1 was involved when 
the cell death trigger activated the intrinsic (mitochondrial-me-
diated) pathway, and KCa1.1 was involved in activation of the 
extrinsic pathway that occurs in response to apoptotic triggers 
such as CD95 (also known as FAS) and Tumor Necrosis Factor 
(TNF) [24].
Contribution to tumor vascularization
Laboratory studies suggest that tumor cells that express Kv10.1 
show significantly higher levels of Vascular Endothelial Growth 
Factor Receptor (VEGF) secretion than controls, and tumors that 
express Kv10.1 have increased vascularization [26]. In addition, 
Kv11.1 expression in glioblastoma increases VEGF secretion 
and appears to exert proangiogenic effects [27].
Potential use as prognostic markers
In a combined clinical and laboratory study of hematopoietic 
neoplasms Kv10.1 was also found to be up-regulated in myelod-
ysplastic syndromes, Chronic Myeloid Leukemia (CML) and al-
most half of the tested Acute Myeloid Leukemia (AML) samples 
in a subtype-dependent fashion, suggesting that Kv10.1 may be 
a novel target for diagnostic, prognostic and/or therapeutic ap-
proaches in AML [28]. Other studies using clinical tumor sam-
ples suggest that Kv10.1 overexpression correlates with worse 
prognosis in head and neck cancer, ovarian cancer and soft tissue 
sarcoma [29-31].
Deranged epigenetic mechanisms
Aberrant methylation of K+ channel gene promoter regions is 
increasingly being recognized in a variety of cancer types [32].
Hypermethylation has been reported for: Kv10.2 in Non-Small 
Cell Lung Cancer (NSCLC) [33,34]; and Kv1.3 in breast cancer 
where it was associated with poorly differentiated tumors [35], 
and also in pancreatic adenocarcinoma [36]. In contrast, hypo-
methylation has been reported for Kca3.1 in NSCLC where it 
was also linked to worse prognosis [37].
Two-Pore Domain Potassium Channels 
and Cancer
K2p channels are made up of four transmembrane segments and 
2 pores (P-loops) in tandem. The family of K2p channels has 
15 members and these are thought to be background channels 
which enable the leak of K+ ions from cells and are open at rest 
[38]. Background or leak K+ conductance is known to stabilize 
the negative cellular resting membrane potential and counter 
balance inward depolarizing currents [39]. K2p channels are im-
portant for baseline cellular activity at rest including membrane 
potential, calcium homeostasis and cell volume regulation. Ev-
idence largely from laboratory studies support the hypothesis 
that alterations of the expression or function of K2p channels in 
cancer cells may play a significant role in cancer development 
and progression [3,6,40].
The 15 K2p channel family members can be further subdivided 
into 6 structural and functional subfamilies [38]:
a. Two-pore, weakly inwardly rectifying (TWIK): TWIK-1 or 
KCNK1, TWIK-2 or KCNK6 and TWIK-3 or KCNK7
b. TWIK-related acid-sensitive: TASK-1 or KCNK3, TASK-3 
or KCNK9 and TASK-5 or KCNK15
c. TWIK-related K+ channel: TREK-1 or KCNK2, TREK-2 or 
KCNK10; and TWIK-related, arachidonic acid-stimulated 
K+ channel: TRAAK or KCNK4
d. TWIK-related alkaline pH-activated K+ channels: TALK-
1 or KCNK16 and TALK-2 or KCNK17; and TASK-2 or 
KCNK5
e. Tandem pore domain halothane-inhibited K+ channels: 
THIK-1 or KCNK13 and THIK-2 or KCNK12
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f. TWIK-related spinal cord K+ channel TRESK or KCNK18
An online database search was performed to discover potential 
novel cancer relationships and tumorigenic mechanisms for all 
K2p genes and findings are provided below [41-43]. It should 
be noted that the following K2p genes have proximate chromo-
somal locations and potentially may exhibit marker correlation: 
KCNK1 (located on 1q42) and KCNK2 (1q41); KCNK3 (2p23) 
and KCNK12 (2p16); KCNK4 (11q13) and KCNK7 (11q13); 
KCNK5 (6p21), KCNK16 (6p21) and KCNK17 (6p21); and 
KCNK10 (14q31) and KCNK13 (14q32). In addition, a search 
of the NHGRI-EBI GWAS catalog was performed to describe 
any SNP-traits associated with cancer [44]. No SNP variants 
were found cataloged with associations with cancer for the 
following K2p genes: KCNK1, KCNK2, KCNK3, KCNK4, 
KCNK5, KCNK7, KCNK9, KCNK12, KCNK13, KCNK15, 
KCNK16, KCNK17 and KCNK18. SNP rs8102476 on KCNK6 
was cataloged as associated with prostate cancer susceptibility 
[45]. SNP rs17124276 on KCNK10 was catalogued as associ-
ated with survival in pancreatic cancer [46]. A summary of K2p 
genes is provided in table 1.
Genomic Contexta Protein Contexta
Gene Alternate names Location Exons AA Function
# length
KCNK1 K2P1.1 TWIK1 1q42-q43 6 336 Probably nonfunctional; may require other proteins for activity
KCNK2 K2P2.1 TREK1 1q41 13 426
Functional; can be opened by certain anesthetics, membrane stretch-
ing, intracellular acidosis, and heat
KCNK3 K2P3.1 TASK1 2p23 3 394
Acid-sensitive potassium channel; activated by the anesthetics hal-
othane and isoflurane
KCNK4 K2P4.1 TRAAK1 11q13.1 7 393
Channel is regulated by polyunsaturated fatty acids, temperature and 
mechanical deformation of the lipid membrane; protein is expressed 
primarily in neural tissues and may be involved in regulating the 
noxious input threshold in dorsal root ganglia neurons; naturally 
occurring read-through transcripts also exist between this gene and 
the downstream Testis Expressed 40 (TEX40) gene
KCNK5 K2P5.1 TASK2 6p21 5 499
Mainly expressed in the cortical distal tubules and collecting ducts 
of the kidney; protein is highly sensitive to external pH
KCNK6 K2P6.1 TWIK2 19q13.1 5 313
Widely expressed; stimulated by arachidonic acid, and inhibited by 
internal acidification and volatile anesthetics
KCNK7 K2P7.1 TWIK3 11q13 4 307 Probably nonfunctional; may require other proteins for activity
KCNK9 K2P9.1 TASK3 8q24.3 5 374
Amplification and overexpression of this gene have been observed 
in several types of human carcinomas; gene is imprinted in the brain, 
with preferential expression from the maternal allele; a mutation in 
this gene was associated with Birk-Barel mental retardation dys-
morphism syndrome
KCNK10 K2P10.1 TREK2 14q31.3 10 538
Stimulated strongly by arachidonic acid and to a lesser degree by mem-
brane stretching, intracellular acidification, and general anesthetics
KCNK12 K2P12.1 THIK2 2p16.3 3 430 Probably nonfunctional; may require other proteins for activity
KCNK13 K2P13.1 THIK1 14q32.11 2 408
Functions include regulating neurotransmitter release, heart rate, 
insulin secretion, neuronal excitability, epithelial electrolyte transport, 
smooth muscle contraction, and cell volume; open channel that can 
be stimulated by arachidonic acid and inhibited by the anesthetic 
halothane
KCNK15 K2P15.1 TASK5 20q13.12 2 330 Probably nonfunctional; may require other proteins for activity
KCNK16 K2P16.1 TALK1 6p21.2-p21.1 8 309
Gene is expressed predominantly in the pancreas and is activated 
at alkaline pH
KCNK17 K2P17.1 TALK2 6p21.1 7 332 Gene is activated at alkaline pH; KCNK3 is a paralog of this gene
KCNK18 K2P18.1 TRESK2 10q25.3 3 384
Mutation in this gene has been found to be associated with migraine 
with aura
Table 1: Two-pore domain potassium channel gene summary.
aFrom NCBI, GeneCards, PubMed and UCSC browser searches.
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syndrome [3,50,52]. Importantly, amplification of the KCNK9 
gene has been reported in breast cancer (detailed further below) 
and melanoma [53,54]. KCNK9 has also been found to be over-
expressed in breast, lung and colorectal cancer [54,55].
KCNK9 is recognized as a proto-oncogene and overexpression 
is known to promote tumor formation and induce resistance to 
hypoxia, and mice injected with NmuMG (mammary epithelial) 
cells overexpressing KCNK9 developed tumors [54]. Pei et al., 
established that the oncogenic potential of KCNK9 depends on 
K+ channel function and showed that a specific point mutation 
(G95E) abolished channel activity and abrogated its oncogenic 
functions, including proliferation in serum deprived media, re-
sistance to apoptosis, and promotion of tumor growth. Hence 
wild-type KCNK9 confers a growth advantage to cells, where-
as the inactivating mutant has no effect on cell growth [56].
Another study showed that KCNK9 channels were expressed 
in the mitochondria of melanoma cells, and were essential for 
maintaining cellular integrity and viability. They found that a 
KCNK9 knockdown melanoma cell line had altered morpholo-
gy, reduced DNA content, decreased metabolic activity and im-
paired mitochondrial function [57].
Taken together, these reports suggest that KCNK9 channels play 
a key role in carcinogenesis [3,50]. Williams et al., found that 
KCNK3 showed altered expression in majority of cancers exam-
ined (13 out of 20) and was upregulated in leukemia, lymphoma, 
and kidney and breast cancer, and underexpressed in sarcoma 
and lung, pancreas, CNS, bladder, colorectal and prostate can-
cers.Whereas, KCNK9 only showed upregulated expression in 
breast cancer, and KCNK15 showed overexpression in breast 
and underexpression in gastrointestinal cancers.
TREK and TRAAK Subfamilies: KCNK2, KCNK10 
and KCNK4
These channels are mechanically-gated and have been shown 
to open by membrane stretch. They are also opened by various 
lipids, including long chain polyunsaturated anionic fatty acids 
and neutral cone-shaped lysophospholipids [58]. KCNK2 or 
TREK-1 channels are activated by volatile anesthetics and may 
be an important target in the action of these drugs [59]. Increased 
KCNK2 expression has been found in prostate cancer samples 
compared to normal epithelium, and reduced proliferation of 
prostate cancer cell lines occurred when KCNK2 was experi-
mentally knocked down [60].
A recent study evaluated KCNK2 expression in prostate cancer 
using Immunohistochemistry (IHC) and found that compared 
with normal prostate tissue, KCNK2 was overexpressed in can-
cer, and was also associated with less favorable clinical prognos-
tic features [61]. Further, both KCNK2 and KCNK10 or TREK-
2 are expressedin the normal human ovary and epithelial ovarian 
cancer, and modulators of KCNK2 in cell cultures have signifi-
cant effects on cell proliferation and apoptosis [62]. KCNK10 is 
also overexpressed in bladder cancer cell lines and is thought to 
partly contribute to cell cycle-dependent growth [63].
TWIK Subfamily: KCNK1, KCNK6, and KCNK7
The weakly inward rectifying channel KCNK1 or TWIK-1 was 
originally cloned from adult kidney and is expressed in many 
other tissues including brain and heart [47,48]. KCNK6 or 
TWIK-2 is the closest relative of KCNK1 and also has wide dis-
tribution [48,49]. Both are inhibited by pharmacological treat-
ments known to lower intracellular pH [49]. KCNK7 or TWIK-3 
however, has not been shown to be a functional channel and may 
require other non-pore-forming proteins for activity [38,50].
To date, none of these TWIK subfamily channels have been 
definitively implicated in having a role in cancer [3,38]. How-
ever, Williams et al., performed an exploratory online cancer 
microarray database study across several cancer types, compar-
ing mRNA expression in cancer to normal tissue, and found the 
following results regarding the top 10% genes both over and un-
der expressed [6]. When compared to normal tissue, significant 
overexpression of KCNK1 was observed in most cancers stud-
ied (including: bladder, brain, breast, cervix, esophageal, head 
and neck, kidney, leukemia, lung, lymphoma and pancreatic) 
while other cancer tissue types showed KCNK1 underexpres-
sion (including: melanoma, prostate and sarcoma). KCNK6 was 
overexpressed in breast and underexpressed in colorectal and es-
ophageal cancers and melanoma.While KCNK7 failed to show 
overexpression in any of the cancer types examined, it showed 
significant underexpression in a range of cancers including: cer-
vical, esophageal, head and neck, and lymphoma and melanoma 
[6].
TASK Subfamily: KCNK3, KCNK9 and KCNK15
The TASK (TWIK-related acid-sensitive) family of K+ chan-
nels share >50% of sequence identity, and within this family 
KCNK15 or TASK-5 has not been shown to be functionally ex-
pressed. Heterodimerization between KCNK3 or TASK-1 and 
KCNK9 or TASK-3 has been demonstrated, and TASK chan-
nels are expressed in the Central Nervous System (CNS) as 
well as heart (KCNK3, KCNK15) and adrenal gland (KCNK3, 
KCNK9) [49]. KCNK3 encodes a protein which is an outwardly 
rectifying channel that is sensitive to changes in extracellular pH 
and is inhibited by extracellular acidification. KCNK3 protein is 
found in brain and cerebellum and is activated by the anesthetics 
halothane and isoflurane, and blocked by bupivacaine [3]. Fur-
ther, KCNK3 expression has been found to be down-regulated in 
patients with colorectal cancer with unfavorable prognosis, and 
as such KCNK3 may be considered a potential prognostic mark-
er for colorectal cancer [51]. Like KCNK3, KCNK9 channels 
also generate outwardly rectifying currents that are modulated 
by a wide range of chemical and physical stimuli such as acidi-
fication and hypoxia, responds similarly to anesthetic agents and 
is normally observed in the brain with particularly strong ex-
pression in the cerebellum.
The KCNK9 gene is imprinted in brain tissue with preferential 
expression from the maternal allele, and a mutation in this gene 
is associated with Birk-Barel mental retardation dysmorphism 
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A recent study demonstrates that KCNK4 or TRAAK is differ-
entially methylated by race in breast cancer, with higher median 
levels being observed in non-Hispanic (nH) black, compared 
with nH white women (further elaborated on below) [64]. Wil-
liams et al., found that: KCNK2 was among the top genes over-
expressed in lung and underexpressed in breast, gastrointestinal 
and head and neck cancers; KCNK10 was among the top genes 
underexpressed in colorectal, kidney, breast and brain cancers; 
and KCNK4 failed to show altered expression in any of the 20 
cancers examined [6].
TALK and TASK-2 Subfamilies: KCNK16, KCNK17 
and KCNK5
This subfamily comprises the TWIK-related alkaline pH-acti-
vated K+ channels plus the related TASK-2 channel, and ex-
pression of all 3 members (KCNK16 or TALK-1, KCNK17 or 
TALK-2 and KCNK5 or TASK-2) is very low in the CNS. These 
channels are stimulated by alkalinization of the external medium 
and are more present in peripheral tissues including kidney, liv-
er, pancreas, and placenta for KCNK5, and mainly in the pancre-
as for KCNK16 and KCNK17. KCNK16 and KCNK17 are also 
strongly activated by Nitric Oxide Species (NOS) and Reactive 
Oxygen Species (ROS) [49]. In a systematic screening study to 
identify novel amplified cancer genes using 975 human cancer 
DNA samples, 750 cell lines and 225 primary tumors, KCNK5, 
KCNK17, and KCNK16 were among eight genes identified in a 
previously uncharacterized amplicon located on 6p21.2. How-
ever, these genes were not observed to be the most frequently 
amplified [65].
Another small study reported significant association between 
cumulative arsenic exposure and KCNK17 methylation levels 
in smoking-unrelated urothelial carcinoma [66]. Taken togeth-
er, these findings which associate KCNK16 and KCNK17 with 
cancer are considered preliminary and need to be validated by 
further studies. KCNK5 expression has been examined in breast 
cancer and is discussed in detail below. Williams et al., found 
that: KCNK16 and KCNK17 failed to show convincing evidence 
of altered expression with the cancers examined; and KCNK5 
was among the top upregulated genes in esophageal, breast and 
lung cancers, and among the top underexpressed genes in leu-
kemia, sarcoma, and colorectal, kidney and liver cancers [6].
THIK Subfamily: KCNK13 and KCNK12
KCNK13 or THIK-1 and KCNK12 or THIK-2 are the tandem 
pore domain halothane-inhibited K+ channels and were origi-
nally isolated from rat brain. Despite a high level of sequence 
homology, KCNK13 produces background K+ currents, where-
as KCNK12 appears to be silent. KCNK13 can be stimulated by 
arachidonic acid and inhibited by the anesthetic halothane [67]. 
A recent study however, shows that both KCNK13 and KCNK12 
are active heteromeric channels, and that they can co-assemble 
and form functional channels in the plasma membrane [68]. To 
date, none of these THIK subfamily channels have been defin-
itively implicated in having a role in cancer. Williams et al., 
found that there was evidence suggestive of KCNK13 overex-
pression in breast cancer, and KCNK12 overexpression in acute 
lymphocytic leukemia and lung cancer and underexpression in 
astrocytoma and glioblastoma [6]. 
TRESK Subfamily: KCNK18
KCNK18 or TRESK is the sole member of the TWIK-related 
spinal cord K+ channel subfamily and is regulated by the cal-
cium/calmodulin-dependent protein phosphatase calcineurin 
and expression has been reported in the human spinal cord [69]. 
A study suggests that the background K+ currents in human 
lymphoma (Jurkat cells) are mediated by KCNK18 [70]. Fur-
ther, a subsequent study showed that positive immunostaining 
for KCNK18 was demonstrated in lymphoblastic cell lines, in 
germinal centers of non-tumoral lymph nodes, and in clinical 
samples of T acute lymphoblastic leukemia/lymphoma, and the 
authors concluded that KCNK18 overexpression is related to 
immune system tumorigenesis [71]. Williams et al., found that 
when compared to normal tissue controls KCNK18 did not show 
altered expression in any of the cancer types examined [6].
The Role of K2p Channels in Breast Can-
cer
The role of K2p channel genes in breast cancer is currently 
emerging and several recent reviews suggest potential clini-
cal utility of K2p channel genes as biomarkers in breast can-
cer [3,4,72]. Williams et al., examined the expression of all 
15 K2p family members and showed that all but 5 showed al-
tered expression in breast cancer (KCNK4, KCNK7, KCNK12, 
KCNK16, KCNK18). K2p genes KCNK1, KCNK3, KCNK5, 
KCNK6, KCNK9, KCNK13, KCNK15, and KCNK17 showed 
overexpression, while KCNK2 and KCNK10 showed underex-
pression [6].
KCNK4
A recent study examined DNA methylation at 1,287 CpG (cy-
tosine-guanine) loci in the promoters of cancer-related genes in 
216 nH black and 301 nH white women with invasive breast 
cancer. Results suggests that KCNK4 is differentially methylat-
ed according to black: white race, with higher median methyl-
ation beta values being observed for nH black women, whether 
using self-report or genotype markers for identification of race 
[64]. The authors also validated these findings using additional 
samples from The Cancer Genome Atlas (TCGA). It is however 
not clear from the report whether KCNK4 methylation is asso-
ciated with a specific subtype, particularly as nH black patients 
in this study are known to have higher prevalence of aggressive 
basal (ER/PR: estrogen/progesterone receptor negative; HER2: 
human epidermal growth factor receptor-2 negative; and cyto-
keratin 5/6 positive and/or HER1 positive) type breast tumors.
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KCNK5
In ER-alpha-positive cell lines (encoded by the ESR1), KCNK5 
expression appears to be under the control of ER-alpha signal-
ing. Specifically, researchers observed an up-regulation of tran-
script encoding KCNK5 in a screen for genes stimulated by 17 
beta-estradiol (E2) in the ER-alpha-positive breast cancer cell 
lines MCF-7 and T47D. Further, chromatin immunoprecipita-
tion assays revealed binding of ER-alpha to the KCNK5 en-
hancer region in E2-treated MCF-7 cells, and estrogen-respon-
sive elements are present in the enhancer region of KCNK5. 
Cells treated with E2 also showed increases in the amplitude 
of pH-sensitive K+ currents which suggests that E2 treatment 
increases the number of active channels at the cell surface.
Finally, the application of small interfering RNA specific for 
KCNK5 decreased pH-sensitive K+ currents and reduced the 
estrogen-induced proliferation of T47D cells, which confirms 
that this channel is required for normal E2-evoked proliferation 
of these cells [73]. In addition, Clarke et al., used a weighted 
gene co-expression network analysis in a recent study to identi-
fy co-regulated gene clusters across 2342 breast cancer samples 
from 13 microarray-based gene expression studies. In this study, 
11 distinct co-expression clusters were identified from 5500 
probe sets. In a cluster of genes that was found to correlate with 
prognosis exclusively for aggressive basal-like type breast can-
cer, upregulation of KCNK5 was associated with poor outcome 
for this subtype. The authors go on to suggest that KCNK5 may 
be a useful clinical marker for this subtype and that further re-
search was needed [74].
KCNK9
Mu et al., first described the KCNK9 gene located at chromo-
somal region 8q24.3 and encoding TASK3 as a potential pro-
to-oncogene. Amplification of the KCNK9 gene was detected 
in 10%, and overexpression of protein was detected in 44% of 
breast tumors, but not in normal tissue controls. Furthermore, 
overexpression of KCNK9 in cell lines promoted tumor forma-
tion and conferred resistance to hypoxia, suggesting that amplifi-
cation and overexpression of KCNK9 provides selective advan-
tage to breast cancer cells [54]. In addition, a subsequent study 
established a direct link between K+ channel activity of KCNK9 
and its proliferative oncogenic function; specifically, K+ chan-
nel activity was required for KCNK9 to promote tumor forma-
tion in nude mice, and a dominant-negative mutant for expres-
sion of the mutant protein inhibited tumorigenicity of wild-type 
KCNK9 [56]. As such, KCNK9 has been found to be frequently 
amplified in breast tumors where it increases proliferation and 
migration in a K+ permeation-dependent manner [4,75].
KCNK9 is a maternally imprinted gene with monoallelic ex-
pression predominantly in brain tissue, but expression has been 
observed in breast tissue - both are of ectodermal origin [52]. 
Hence it is theorized that as KCNK9 is a maternally imprinted 
gene, overexpression may occur due to relative Loss of Meth-
ylation (LOM) and subsequent functionally biallelic expression 
which may be equivalent to duplication of an active allele [76].
Early studies have reported frequent LOM at KCNK9 differ-
entially methylated regions with biallelic expression in some 
breast tumor biopsies and random periareolar fine-needle aspi-
rates from non-cancerous breast in high-risk, nH black wom-
en, and also that LOM is associated with more aggressive tri-
ple-negative (TN; negative for ER/PR/HER2 status determined 
by IHC) breast cancer [76]. Furthermore, it has been suggested 
that for TN disease, nH black women have higher KCNK9 LOM 
levels compared to nH white, 90% versus 67% respectively [76].
However, the epidemiologic data to date characterizing KCNK9 
is limited [52,76-78].
KCNK12
Molecular changes involved in histologic tubular breast car-
cinoma were examined using microarray-based comparative 
genomic hybridization focusing on 287 genomic target clones 
of oncogenes and tumor suppressor genes in 21 patient sam-
ples of tubular carcinoma. The highest frequencies for DNA 
sequence copy number losses were detected for CDH13 and 
MSH2/KCNK12 (in 86% and 52% of the samples, respectively).
However, because it was not the most prominent copy number 
change location, KCNK12 loss was not further evaluated in the 
study [79]. 
Analysis of The Cancer Genome Atlas (TCGA) data 
Recently Dookeran et al., systematically evaluated associations 
of K2p gene expression and DNA methylation with TN sub-
type using TCGA invasive breast cancer data. Overexpression 
of KCNK5, KCNK9 and KCNK12, and underexpression of 
KCNK6 and KCNK15, were significantly associated with TN 
vs. luminal A (ER/PR+ and HER2-) subtype (Bonferroni-cor-
rected p < 0.0033). A total of 195 (114 hypomethylated and 
81 hypermethylated) CpG loci were found to be significantly 
associated with TN subtype (Bonferroni-corrected p < 8.22 × 
10−8). Significantly negatively correlated expression patterns 
that were differentially observed in TN vs. luminal A subtype 
were demonstrated for KCNK2, KCNK5 and KCNK9. CpG 
loci listed for KCNK5 and KCNK9 all showed relative hypo-
methylation for probability of TN vs. luminal A subtype. Re-
garding specificity for association of K2p expression with tumor 
vs. normal sample-type, the MEXPRESS web tool was used to 
visualize expression and clinical TCGA data [80], and showed 
that KCNK9 and KCNK12 overexpression appeared to be asso-
ciated with tumor type, while KCNK5 overexpression appeared 
to have marginal association. Sensitivity analyses that examined 
associations of K2p expression and other subtypes related to 
TN status (ER/PR-negative, basal and Integrative Cluster type 
10) also showed consistency with similar mRNA expression 
patterns. The authors concluded that TN subtype was associat-
ed with distinct K2p expression patterns, and both KCNK5 and 
KCNK9 overexpression appeared to be functionally related to 
CpG loci hypomethylation [81]. However, additional examina-
tion of breast cancer recurrence/progression for select TCGA 
Citation: Dookeran KA, Auer P (2017) The Emerging Role of Two-Pore Domain Potassium Channels in Breast Cancer. J Glob Epidemiol Environ Health 2017: 27-36.
  J Glob Epidemiol Environ Health 2017: 27-36.                                                                                                                                                                                      .07.
K2p gene expression did not reveal significant associations in 
age and race adjusted Cox models (Table 2).
Another study in TN breast cancer cells suggests that inhibition 
of intermediate-conductance KCa channel KCNN3 with specific 
blockers including the antifungal clotrimazole, suppressed cell 
proliferation, migration and epithelial-mesenchymal transition 
[83]. Sun et al., suggest that antibody-based KCNK9 targeting is 
a promising therapeutic strategy in KCNK9 overexpressing ma-
lignancies and showed that a monoclonal antibody (Y4) against 
KCNK9 extracellular-domain effectively inhibits growth of hu-
man lung cancer xenografts and breast cancer metastasis in mice 
[84]. Investigators have also been researching whether loss of 
KCNK9 imprint-control and/or differential methylation could 
be adapted in novel approaches for clinical diagnosis and target-
ed therapy in aggressive TN breast cancer [52,76-78]. Current 
molecular epidemiologic data characterizing K2p channel genes 
in breast cancer is however limited, and lacks a systematic ex-
amination approach, with few peer-review publications, and this 
is considered a critical knowledge deficiency to progress in the 
field.
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